Open AccessRisk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis
Author(s) -
Tiphaine Lenfant,
S. Ben Salah,
Gaëlle Leroux,
Elodie Bousquet,
Véronique Le Guern,
François Chasset,
Camille Françès,
Nathalie Morel,
J. Chezel,
Thomas Papo,
Patrice Cacoub,
Luc Mouthon,
G. Guettrot-Imbert,
Pascal Cohen,
Alexis Régent,
Martine MaugetFaÿsse,
JeanCharles Piette,
M. Jallouli,
Nathalie Costédoat-Chalumeau
Publication year - 2020
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keaa157
Subject(s) - medicine , hydroxychloroquine , retinopathy , cumulative dose , creatinine , univariate analysis , odds ratio , renal function , gastroenterology , endocrinology , multivariate analysis , diabetes mellitus , covid-19 , disease , infectious disease (medical specialty)
HCQ is an essential medication in SLE, proven to lengthen survival and reduce flares. Its use, however, is limited by its rare but severe ophthalmological complications. Here, we aimed to analyse factors associated with HCQ retinopathy including HCQ blood levels.